FGF21 acts as a downstream metabolic target of oncogenes or as a corrective metabolic suppressor in tumor lesions (26, 27), with its overexpression antagonizing the development of liver and pancreatic cancers (28, 29). This evidence concerns the gene FGF21 and familial pancreatic carcinoma.